MS Ireland is planning to make a submission to the HSE regarding Sativex. If you have been affected by the lack of availability of Sativex, please take a few minutes to complete this short survey, which will help us to develop a strong submission.
Happy New Year from the MS & Me Blog Team. Here’s what 2017 looks like from here...
MS Ireland funds new mindfulness research project at NUI Galway
Ocrelizumab is a new medication which has recently been shown in three, large phase-three clinical trials to have beneficial effects in both relapsing-remitting and primary progressive MS. When available, Ocrelizumab will be a welcome addition to the number of drugs currently licensed for relapsing-remitting MS and may also be beneficial to people with primary progressive MS.
This week, Emma Rogan reflects on the best of what makes this time of the year enjoyable. Warning, it includes many cups of tea!
Fiona O’Reilly (48) has been living with Multiple Sclerosis (MS) for the last 3 years. Some days are worse than others. Some days she can barely move at all. On others, the loss of feeling in her feet and her lack of balance put her at constant risk.
The HSE released the Service Plan for 2017 on 14th December. The Service Plan details the delivery of health services that the HSE will provide directly, and through a range of funded agencies, in 2017. The plan can be accessed here
© 2010 - 2024 Multiple Sclerosis Society of Ireland